U.S. paves way for Novartis to copy Amgen biotech drug
July 24, 2014 at 04:08 AM EDT
July 24 (Reuters) - U.S. regulators have accepted an application by Sandoz - the generics arm of Novartis - seeking approval for a copycat version of Amgen's drug Neupogen, or filgrastim, for patients with low white blood cell counts.